These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 27335205)

  • 21. The Innovative Medicines Initiative -10 Years of Public-Private Collaboration.
    Laverty H; Meulien P
    Front Med (Lausanne); 2019; 6():275. PubMed ID: 31850354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Competition: Unlikely partnerships.
    Savage N
    Nature; 2016 May; 533(7602):S56-8. PubMed ID: 27167391
    [No Abstract]   [Full Text] [Related]  

  • 23. The innovative medicines initiative: a case study for new ways of working in drug R&D.
    Laverty H; Goldman M
    Future Med Chem; 2014 Apr; 6(5):489-91. PubMed ID: 24649951
    [No Abstract]   [Full Text] [Related]  

  • 24. Strategies for bringing drug delivery tools into discovery.
    Kwong E; Higgins J; Templeton AC
    Int J Pharm; 2011 Jun; 412(1-2):1-7. PubMed ID: 21421040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Innovative Medicines Initiative moves translational immunology forward.
    Goldman M; Wittelsberger A; De Magistris MT
    Eur J Immunol; 2013 Feb; 43(2):298-302. PubMed ID: 23534061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tuberculosis drug discovery needs public-private consortia.
    Cole ST
    Drug Discov Today; 2017 Mar; 22(3):477-478. PubMed ID: 27717851
    [No Abstract]   [Full Text] [Related]  

  • 27. The role of public-private partnerships in addressing the biomedical innovation challenge.
    Said M; Zerhouni E
    Nat Rev Drug Discov; 2014 Nov; 13(11):789-90. PubMed ID: 25359362
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Aiming for zero blindness].
    Nakazawa T
    Nippon Ganka Gakkai Zasshi; 2015 Mar; 119(3):168-93; discussion 194. PubMed ID: 25854109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug discovery: new models for industry-academic partnerships.
    Tralau-Stewart CJ; Wyatt CA; Kleyn DE; Ayad A
    Drug Discov Today; 2009 Jan; 14(1-2):95-101. PubMed ID: 18992364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cohorts and registers: Which public/private partnerships to choose?].
    Jouan-Flahault C; Landais P; Thomas R; Parker S; Genevaz D
    Presse Med; 2012 May; 41 Suppl 1():S15-9. PubMed ID: 22464892
    [No Abstract]   [Full Text] [Related]  

  • 31. Reflections on the Innovative Medicines Initiative.
    Goldman M
    Nat Rev Drug Discov; 2011 May; 10(5):321-2. PubMed ID: 21532547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Partnerships for better neglected disease drug discovery and development: how have we fared?
    Sunyoto T
    Expert Opin Drug Discov; 2020 May; 15(5):531-537. PubMed ID: 32129688
    [No Abstract]   [Full Text] [Related]  

  • 33. The innovative medicines initiative: a public private partnership model to foster drug discovery.
    Vaudano E
    Comput Struct Biotechnol J; 2013; 6():e201303017. PubMed ID: 24688725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug discovery and development for neglected diseases: the DNDi model.
    Chatelain E; Ioset JR
    Drug Des Devel Ther; 2011 Mar; 5():175-81. PubMed ID: 21552487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improving R&D productivity of pharmaceutical companies through public-private partnership: experiences from the Innovative Medicines Initiative.
    Laverty H; Gunn M; Goldman M
    Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):545-8. PubMed ID: 23136843
    [No Abstract]   [Full Text] [Related]  

  • 36. The In Silico Drug Discovery Toolbox: Applications in Lead Discovery and Optimization.
    Bruno A; Costantino G; Sartori L; Radi M
    Curr Med Chem; 2019; 26(21):3838-3873. PubMed ID: 29110597
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
    Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
    J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medications development for substance-use disorders: contextual influences (dis)incentivizing pharmaceutical-industry positioning.
    Janero DR
    Expert Opin Drug Discov; 2014 Nov; 9(11):1265-79. PubMed ID: 25162124
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Partners in discovery.
    Fuyuno I
    Nature; 2018 Mar; 555(7697):S60. PubMed ID: 29565400
    [No Abstract]   [Full Text] [Related]  

  • 40. A pan-serotype antiviral to prevent and treat dengue: A journey from discovery to clinical development driven by public-private partnerships.
    Goethals O; Voge NV; Kesteleyn B; Chaltin P; Jinks T; De Marez T; Koul A; Draghia-Akli R; Neyts J; Van Loock M
    Antiviral Res; 2023 Feb; 210():105495. PubMed ID: 36567021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.